Table 1.
Included studies on effect of orlistat on weight loss
| Study population | Mean age (years) | Mean BMI | Mean weight (kg) | Comparison | Attrition (% drug/placebo) | Cointerventions | |
|---|---|---|---|---|---|---|---|
| Bakrisw1 | 554 with hypertension, 1 year follow-up, (US) | 53 | 35.6 | 101 | Orlistat 120 mg three times daily (n=278); placebo (n=276) | 42/61 | 2.5 MJ/day deficit diet; educational literature |
| Bernew2 | 220 with type 2 diabetes receiving oral hypoglycaemics, 1 year follow-up (Sweden) | 59 | 32.7 | 96 | Orlistat 120 mg three times daily (n=111); placebo (n=109) | 14/14 | 2.5 MJ/day deficit diet; exercise counselling; educational package |
| Broomw3 | 531 with hypertension, impaired glucose tolerance, or dyslipidaemia, 1 year follow-up (UK) | 46 | 37.1 | 101 | Orlistat 120 mg three times daily (n=265); placebo (n=266) | 30/40 | 2.5-3.8 MJ/day deficit diet; food diary |
| Davidsonw4 | 892 followed for 1 year and a second weight maintenance year, (UK) | 46 | 37.1 | 101 | Orlistat 120 mg three times daily (n=668); placebo (n=224) | 31/41 | 2.5-3.3 MJ/day deficit diet; exercise counselling’ food diary |
| Derosaw5 | 50 with dyslipidaemia, 1 year follow-up (Italy) | 52 | 31.9 | 95 | Orlistat 120 mg three times daily (n=27); placebo (n=23) | 7/0 | 6.3 MJ/day deficit diet |
| Finerw6 | 228 followed for 1 year (UK) | 41 | 36.8 | 98 | Orlistat 120 mg three times daily (n=114); placebo (n=114) | 36/42 | 2.5-3.8 MJ/day deficit diet |
| Hauptmanw7 | 635 followed for 1 year and a second weight maintenance year (US) | 42 | 36 | 101 | Orlistat 60 mg three times daily (n=213); orlistat 120 mg three times daily (n=210); placebo (n=212) | 28/28/42 | 5.0-6.3 MJ/day diet; exercise; food diary; educational video |
| Hollanderw8 | 322 with type 2 diabetes, 1 year follow-up (US) | 55 | 34.3 | 100 | Orlistat 120 mg three times daily (n=63); placebo (n=159) | 15/28 | 2.1 MJ/day deficit diet |
| Kelleyw9 | 550 with type 2 diabetes, 1 year follow-up (US) | 58 | 35.7 | 102 | Orlistat 120 mg three times daily (n=274); placebo (n=276) | 50/54 | 2.5-3.3 MJ/day deficit diet; exercise counselling; food records |
| Krempfw10 | 696 followed for 18 months (France) | 41 | 36.1 | 97 | Orlistat 120 mg three times daily (n=346); placebo (n=350) | 35/43 | 20% energy reduced diet, increased by 10% if weight stable; food diary |
| Lindgardew11 | 376 with type 2 diabetes, hypertension or dyslipidaemia, 1 year follow-up (Sweden) | 53 | 33.2 | 96 | Orlistat 120 mg three times daily (n=190); placebo (n=186) | 16/12 | 2.5-3.8 MJ/day deficit diet; exercise; educational package |
| Milesw12 | 156 with type 2 diabetes receiving oral hypoglycaemics, 1 year follow-up (US and Canada) | 53 | 35.4 | 102 | Orlistat 120 mg three times daily (n=255); placebo (n=261) | 35/44 | 2.5-3.3 MJ/day deficit diet; exercise |
| Rossnerw13 | 729 followed for 1 year and a second weight maintenance year (Europe) | 44 | 35.1 | 98 | Orlistat 120 mg three times daily (n=244); placebo (n=243) | 26/35 | 2.5 MJ/day deficit diet; food diary |
| Sjostromw14 | 688 followed for 1 year and a second weight maintenance year (Europe) | 45 | 36.1 | 100 | Orlistat 120 mg three times daily (n=345); placebo (n=343) | 17/20 | 2.5-3.8 MJ/day deficit diet |
| Swinburnw15 | 339 with ≥1 cardiovascular risk factor, 1 year follow-up (Australia and New Zealand) | 52 | 37.8 | 87 | Orlistat 120 mg three times daily (n=170); placebo (n=169) | 22/19 | Diet and exercise counselling |
| XENDOSw16 | 3305 patients (21% with impaired glucose tolerance), 4 year follow-up (Sweden) | 43 | 37.3 | 111 | Orlistat 120 mg three times daily (n=1650); placebo (n=1655) | 48/66 | 3.3 MJ/day deficit diet; exercise counselling |